Literature DB >> 17608509

Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer.

Flaubert Mbeunkui1, Brandon J Metge, Lalita A Shevde, Lewis K Pannell.   

Abstract

Proteins secreted (the secretome) from cancer cells are potentially useful as biomarkers of the disease. Using LC-MS/MS, the secreted proteomes from a series of isogenic breast cancer cell lines varying in aggressiveness were analyzed by mass spectrometry: nontumorigenic MCF10A, premalignant/tumorigenic MCF10AT, tumorigenic/locally invasive MCF10 DCIS.com, and tumorigenic/metastatic MCF 10CA cl. D. Proteomes were obtained from conditioned serum-free media, partially fractionated using a small reverse phase C2 column, and digested with trypsin for analysis by LC-MS/MS, using a method previously shown to give highly enriched secreted proteomes (Mbeunkui et al. J. Proteome Res. 2006, 5, 899-906). The search files produced from five analyses (three separate preparations) were combined for database searching (Mascot) which produced a list of over 250 proteins from each cell line. The aim was to discover highly secreted proteins which changed significantly in abundance corresponding with aggressiveness. The most apparent changes were observed for alpha-1-antichymotrypsin and galectin-3-binding protein which were highly secreted proteins from MCF10 DCIS.com and MCF10CA cl. D, yet undetected in the MCF10A and MCF10AT cell lines. Other proteins showing increasing abundance in the more aggressive cell lines included alpha-1-antitrypsin, cathepsin D, and lysyl oxidase. The S100 proteins, often associated with metastasis, showed variable changes in abundance. While the cytosolic proteins were low (e.g., actin and tubulin), there was significant secretion of proteins often associated with the cytoplasm. These proteins were all predicted as products of nonclassical secretion (SecretomeP, Center for Biological Sequence Analysis). The LC-MS/MS results were verified for five selected proteins by western blot analysis, and the relevance of other significant proteins is discussed. Comparisons with two other aggressive breast cancer cell lines are included. The protein with consistent association with aggressiveness in all lines, and in unrelated cancer cells, was the galectin-3-binding protein which has been associated with breast, prostate, and colon cancer earlier, supporting the approach and findings. This analysis of an isogenic series of cell lines suggests the potential usefulness of the secretome for identifying prospective markers for the early detection and aggressiveness/progression of cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608509      PMCID: PMC2584611          DOI: 10.1021/pr060629m

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  81 in total

Review 1.  Fibronectin and its integrin receptors in cancer.

Authors:  E Ruoslahti
Journal:  Adv Cancer Res       Date:  1999       Impact factor: 6.242

2.  Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum.

Authors:  W M Zhang; P Finne; J Leinonen; S Vesalainen; S Nordling; U H Stenman
Journal:  Clin Chem       Date:  1999-06       Impact factor: 8.327

3.  Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions.

Authors:  J A Uría; M Ståhle-Bäckdahl; M Seiki; A Fueyo; C López-Otín
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

4.  Annexin 2 promotes the formation of lipid microdomains required for calcium-regulated exocytosis of dense-core vesicles.

Authors:  Sylvette Chasserot-Golaz; Nicolas Vitale; Emeline Umbrecht-Jenck; Derek Knight; Volker Gerke; Marie-France Bader
Journal:  Mol Biol Cell       Date:  2005-01-05       Impact factor: 4.138

5.  Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone.

Authors:  K Jacob; M Webber; D Benayahu; H K Kleinman
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

Review 6.  S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis.

Authors:  G V Sherbet; M S Lakshmi
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

Review 7.  Chemopreventive agents: protease inhibitors.

Authors:  A R Kennedy
Journal:  Pharmacol Ther       Date:  1998-06       Impact factor: 12.310

8.  SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines.

Authors:  C Gilles; J A Bassuk; H Pulyaeva; E H Sage; J M Foidart; E W Thompson
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

9.  Serum alpha-1 proteinase inhibitor in advanced cancer: mass variants and functionally inert forms.

Authors:  R K Chawla; D H Lawson; P R Sarma; D W Nixon; J Travis
Journal:  Cancer Res       Date:  1987-02-15       Impact factor: 12.701

10.  Prognostic value of cathepsin D in breast cancer.

Authors:  B R Westley; F E May
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

View more
  36 in total

Review 1.  Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting.

Authors:  Georgina S Butler; Christopher M Overall
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

2.  Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.

Authors:  Marc Warmoes; Janneke E Jaspers; Thang V Pham; Sander R Piersma; Gideon Oudgenoeg; Maarten P G Massink; Quinten Waisfisz; Sven Rottenberg; Epie Boven; Jos Jonkers; Connie R Jimenez
Journal:  Mol Cell Proteomics       Date:  2012-02-24       Impact factor: 5.911

3.  Global secretome analysis identifies novel mediators of bone metastasis.

Authors:  Mario Andres Blanco; Gary LeRoy; Zia Khan; Maša Alečković; Barry M Zee; Benjamin A Garcia; Yibin Kang
Journal:  Cell Res       Date:  2012-06-12       Impact factor: 25.617

4.  Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis.

Authors:  Lei Jin; Yan Zhang; Hui Li; Ling Yao; Da Fu; Xuebiao Yao; Lisa X Xu; Xiaofang Hu; Guohong Hu
Journal:  Cell Res       Date:  2012-06-12       Impact factor: 25.617

5.  Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation.

Authors:  Michael J V White; David Roife; Richard H Gomer
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

6.  Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model.

Authors:  Jae Young So; Hong Jin Lee; Pavel Kramata; Audrey Minden; Nanjoo Suh
Journal:  Mol Cell Pharmacol       Date:  2012-01-01

7.  Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.

Authors:  Pavel Gromov; Irina Gromova; Jakob Bunkenborg; Teresa Cabezon; José M A Moreira; Vera Timmermans-Wielenga; Peter Roepstorff; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2009-11-23       Impact factor: 6.603

Review 8.  Breast tumor microenvironment: proteomics highlights the treatments targeting secretome.

Authors:  Shui-Tein Chen; Tai-Long Pan; Hsueh-Fen Juan; Tai-Yuan Chen; Yih-Shyan Lin; Chun-Ming Huang
Journal:  J Proteome Res       Date:  2008-02-22       Impact factor: 4.466

Review 9.  Methodologies to decipher the cell secretome.

Authors:  Paromita Mukherjee; Sridhar Mani
Journal:  Biochim Biophys Acta       Date:  2013-01-31

Review 10.  Cancer and the tumor microenvironment: a review of an essential relationship.

Authors:  Flaubert Mbeunkui; Donald J Johann
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-14       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.